The research institute in EuBiologics utilizes its specialized technologies and experiences in vaccine product development to develop the vaccines for bacterial epidemics, with the primary goal of health promotion of children in the developing countries.
After successfully launching its first product, Euvichol®, in the end of 2015, it has expedited its researches on new products, including preventative vaccines for new epidemics and bacterial vaccines for antibiotic resistance. It is anticipating new launches around 2020.
Product Overview (Development Finished)
Euvichol®, the first oral cholera vaccine developed in Korea.